GILD

Gilead Sciences Inc. is a research‑driven biopharmaceutical company that discovers, develops and markets therapeutic medicines, most notably antiviral drugs for HIV/AIDS, hepatitis B and C, and more recently COVID‑19, as well as oncology, inflammatory and cell‑therapy products. It operates within the biotechnology and pharmaceutical sector, leveraging a strong R&D pipeline and strategic partnerships to bring new treatments to market. Gilead is recognized as a global leader in antiviral therapy, having built a dominant position with flagship HIV regimens and breakthrough hepatitis C cures, and is actively expanding its presence in cancer and specialty disease areas.